Patient- and Caregiver-Informed Considerations for the Design and Implementation of Generative AI–Supported Patient-Centered Clinical Decision Support: Qualitative Study - Summary - MDSpire
Advertisement
Patient- and Caregiver-Informed Considerations for the Design and Implementation of Generative AI–Supported Patient-Centered Clinical Decision Support: Qualitative Study
To gather patient and caregiver perspectives on the use of generative AI in patient-centered clinical decision support (PC CDS) and generate a prioritized list of considerations for design and implementation.
Approach:
Study Design and Participant Selection: Conducted 6 qualitative small group discussions with 16 participants, including patient and caregiver advocates, to elicit perspectives on generative AI in PC CDS.
Discussion Guide Development: Developed a semistructured discussion guide to facilitate conversations around generative AI use cases in PC CDS, refined through cognitive debriefings.
Key Findings:
Patient and caregiver perspectives on generative AI in PC CDS are not well represented in existing literature.
There is a recognized need for recommendations driven by patients in the design and deployment of AI tools in healthcare.
Interpretation:
Incorporating patient and caregiver insights into the development of generative AI tools for PC CDS is essential.
Limitations:
The sample size was limited to 16 participants, which may not fully represent the broader patient and caregiver population.
The qualitative nature of the study may limit the generalizability of the findings.
Conclusion:
Integrating patient and caregiver perspectives in the design and implementation of generative AI in healthcare decision-making is necessary.
A regional UK audit found wide variation in imaging intervals among patients referred for mechanical thrombectomy and identified potentially modifiable barriers to timely vascular imaging.
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.